Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 426-436

  John Camm, A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adverse events; Atrial fibrillation; Bisphosphonates; Cardiovascular; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; NONHUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SICK SINUS SYNDROME; STROKE;

ANIMALS; ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 77951922997     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.014     Document Type: Review

References (36)

1. Facts and Statistics About Osteoporosis and Its Impact International Osteoporosis Foundation, Accessed February 22, 2010. http://www.iofbonehealth.org/facts-and-statistics.html.
2. Bone Health and Osteoporosis: A Report of the Surgeon General 2004, US Dept of Health and Human Services, Office of the Surgeon General, Rockville, Md.
3. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356:1809-1822. HORIZON Pivotal Fracture Trial.
4. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007, 357:1799-1809. HORIZON Recurrent Fracture Trial.
5. Cummings S, Schwartz AV, Black DM Alendronate and atrial fibrillation. N Engl J Med. 2007, 356:1895-1896.
6. Karam R, Camm J, McClung M Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007, 357:712-713.
7. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008, 168:826-831.
8. Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009, 103:824-828.
9. Abrahamsen B, Eiken P, Brixen K Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009, 265:581-592.
10. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study. BMJ. 2008, 336:813-816.
11. Bisphosphonates: Atrial fibrillation. Drug Safety Update 2008, 1:4.
12. Loke YK, Jeevanantham V, Singh S Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf. 2009, 32:219-228.
13. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates US Food and Drug Administration, Accessed October 5, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
14. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: A population-based study. J Am Geriatr Soc. 2002, 50:1644-1650.
15. Magaziner J, Fredman L, Hawkes W, et al. Changes in functional status attributable to hip fracture: A comparison of hip fracture patients to community-dwelling aged. Am J Epidemiol. 2003, 157:1023-1031.
16. Browner WS, Pressman AR, Nevitt MC, et al. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke. 1993, 24:940-946.
17. Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A Bone changes and carotid atherosclerosis in postmenopausal women. Stroke. 1997, 28:1730-1732.
18. Vogt MT, San Valentin R, Forrest KY, et al. Bone mineral density and aortic calcification: The Study of Osteoporotic Fractures. J Am Geriatr Soc. 1997, 45:140-145.
19. Tankó LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women [published correction appears in J Bone Miner Res. 2006;21:352]. J Bone Miner Res. 2005, 20:1912-1920.
20. Johnell O, Kanis JA, Odén A, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004, 15:38-42.
21. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int. 2004, 15:108-112.
22. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone. 2003, 32:468-473.
23. von der Recke P, Hansen MA, Hassager C The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999, 106:273-278.
24. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996, 348:1535-1541. Fracture Intervention Trial Research Group.
25. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998, 280:2077-2082.
26. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 1999, 282:1344-1352. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
27. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000, 11:83-91. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
28. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004, 19:1241-1249. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
29. Kannel WB, Benjamin EJ Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008, 92:17-40.
30. Cauley JA, Ensrud KE Considering competing risks...not all black and white. Arch Intern Med. 2008, 168:793-795.
31. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997, 96:2455-2461.
32. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998, 98:946-952.
33. Stewart S, Hart CL, Hole DJ, McMurray JJ Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001, 86:516-521.
34. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J. 1996, 17(Suppl C):48-51.
35. Boos CJ, Anderson RA, Lip GY Is atrial fibrillation an inflammatory disorder?. Eur Heart J. 2006, 27:136-149.
36. Fraunfelder FW, Fraunfelder FT Bisphosphonates and ocular inflammation. N Engl J Med. 2003, 348:1187-1188.